A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...

Iovance Biotherapeutics could be a few months away from a first regulatory approval for lifileucel, which could be the first cell-based therapy for a solid tumour in the US. The FDA has formally ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with ...

In addition, Iovance will share five-year outcome data from the C-144-01 study involving lifileucel for advanced melanoma, as well as a poster detailing a Phase 2 study design for lifileucel in ...

Recently, personalized, autologous tumor-infiltrating lymphocyte therapy has become a US Food and Drug Administration–approved second-line option; lifileucel demonstrates durable response ...

Trials testing the TIL therapy, called lifileucel, before FDA approval showed a response rate of 32% among 153 patients. Lifileucel is approved for patients whose melanoma has progressed despite ...

Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 ...

In addition, five-year outcomes data from the C-144-01 study of lifileucel monotherapy in patients with advanced melanoma, and a poster on study design for lifileucel in frontline advanced non ...